Evofem Biosciences, Inc.
EVFM- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001618835
No open-market purchases or sales by Evofem Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Evofem Biosciences, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 83 | 1 | 72 | −10 |
| Shares | 36.2M | 66 | 26.8M | −9.44M (−26.1%) |
| Value | $40.9M | $0 | $19.8M | −$21.1M (−51.7%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Evofem Biosciences, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Fuller & Thaler Asset Management, Inc. | 1,079,860 | $798.0K | 0.01% |
| Steel Peak Wealth Management LLC | 60,000 | $44.0K | 0.00% |
| Kestra Advisory Services, LLC | 31,014 | $23.0K | 0.00% |
| Bedel Financial Consulting, Inc. | 22,500 | $17.0K | 0.01% |
| Jane Street Group, LLC | 21,548 | $16.0K | 0.00% |
| Buckingham Strategic Wealth, LLC | 18,524 | $14.0K | 0.00% |
| YHB Investment Advisors, Inc. | 12,000 | $9.00K | 0.00% |
| Gofen & Glossberg LLC | 10,000 | $7.00K | 0.00% |
| EP Wealth Advisors, LLC | 10,000 | $7.00K | 0.00% |
| Modera Wealth Management, LLC | 10,000 | $7.00K | 0.00% |
| Laffer Tengler Investments | 230 | $169 | 0.00% |
Sold out (21)
Institutions that held Evofem Biosciences, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Renaissance Technologies LLC | 1,507,888 | $1.70M |
| Heartland Advisors Inc | 1,100,000 | $1.24M |
| Taylor Wealth Management Partners | 508,148 | $574.0K |
| Ergoteles LLC | 349,700 | $395.0K |
| ExodusPoint Capital Management, LP | 118,384 | $134.0K |
| Parallax Volatility Advisers, L.P. | 105,294 | $119.0K |
| Cubist Systematic Strategies, LLC | 104,374 | $118.0K |
| Tower Research Capital LLC (TRC) | 63,164 | $71.0K |
| LMR Partners LLP | 47,626 | $54.0K |
| AQR Capital Management LLC | 31,743 | $36.0K |
| XTX Topco Ltd | 20,982 | $24.0K |
| Boothbay Fund Management, LLC | 20,659 | $23.0K |
| Y-Intercept (Hong Kong) Ltd | 18,815 | $21.0K |
| Grantham, Mayo, Van Otterloo & Co. LLC | 12,821 | $14.0K |
| Squarepoint Ops LLC | 11,271 | $13.0K |
| Deutsche Bank AG | 9,639 | $11.0K |
| New York State Common Retirement Fund | 692 | $1.00K |
| Citigroup Inc | 1,000 | $1.00K |
| Captrust Financial Advisors | 1,263 | $1.00K |
| Blume Capital Management, Inc. | 34 | $0 |
| Strategic Blueprint, LLC | 102 | $0 |
Not filed for Q3 2021 yet (1)
Institutions that held Evofem Biosciences, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| CWM, LLC | 66 | $0 |